A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Antivirals (Primary) ; Ledipasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary) ; Tegobuvir (Primary) ; Vedroprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 03 Feb 2018 The study had been Discontinued in Austria.
- 04 Jan 2018 The study had been completed in Spain.
- 28 Dec 2017 This trial has been completed in Germany.